BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32736936)

  • 1. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Elbanna M; Shiue K; Edwards D; Cerra-Franco A; Agrawal N; Hinton J; Mereniuk T; Huang C; Ryan JL; Smith J; Aaron VD; Burney H; Zang Y; Holmes J; Langer M; Zellars R; Lautenschlaeger T
    Clin Lung Cancer; 2021 May; 22(3):e342-e359. PubMed ID: 32736936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
    JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
    Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
    Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
    Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
    Wink KCJ; Löck S; Rossi M; van Baardwijk A; Belderbos J; de Ruysscher D; Troost EGC
    Radiother Oncol; 2019 Feb; 131():120-126. PubMed ID: 30773178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
    Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
    Liu J; Hui C; Ladbury C; Waddington T; Erhunmwunsee L; Raz D; Kim J; Salgia R; Chenery S; Pearlstein D; Schwer A; Amini A
    Clin Lung Cancer; 2021 Sep; 22(5):e678-e683. PubMed ID: 33712362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
    Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
    Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
    Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
    Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
    Ayoub Z; Ning MS; Brooks ED; Kang J; Welsh JW; Chen A; Gandhi S; Heymach JV; Vaporciyan AA; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):261-269. PubMed ID: 32044413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
    Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
    Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England.
    Khakwani A; Harden S; Beckett P; Baldwin D; Navani N; West D; Hubbard R
    Thorax; 2020 Mar; 75(3):237-243. PubMed ID: 31879316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
    Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis.
    Verstegen NE; Oosterhuis JW; Palma DA; Rodrigues G; Lagerwaard FJ; van der Elst A; Mollema R; van Tets WF; Warner A; Joosten JJ; Amir MI; Haasbeek CJ; Smit EF; Slotman BJ; Senan S
    Ann Oncol; 2013 Jun; 24(6):1543-8. PubMed ID: 23425947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.